Details
October 30, 2013
Office-Based Treatment For Opioid Use Disorders Webinar
The American Osteopathic Academy of Addiction Medicine (AOAAM) invites you to join us for a live webcast training on the Office-Based Treatment of Opioid Dependence utilizing Buprenorphine, with an additional focus on Methadone and Naltrexone. The program will provide up-to-date and evidence-based information to support training of health professionals and to address complex issues of addiction.
Saturday Presenter:
Stephen A. Wyatt, DO
Addiction Psychiatrist, Co-Chair SAMHSA Buprenorphine Expert Panel,
Middlesex Hospital, Middletown, CT
Wednesday Presenter:
William R. Morrone, DO, MS, ACOFP, ASAM, DAAPM, FACFEI
Assistant Program Director - Family Medicine
Consultant to Department of Psychiatry
Consultant to Department of Pediatrics
Synergy Medical Education Alliance
Michigan State University
Central Michigan University - School of Medicine
Office of the Medical Examiner
Other Presenters:
Anthony Dekker, DO, FACOFP, FAOAAM
Director of Addiction Medicine
Directorate of Behavioral Health
Ft. Belvoir Community Hospital
Ft. Belvoir, VA 22060
Click here to register for the Oct 12th webinar!
Click here to register for the Oct 30th webinar!
Click here to register for the Nov 9th webinar!
Click here to register for the Nov 20th webinar!
Register ASAP as space is limited.
This live webcast, in conjunction with a 3.75 hour online self-study and exam, will provide the required 8 hours needed to obtain the waiver to prescribe buprenorphine in the office based setting.
For questions, please contact Lara Renucci at pcssmat@aoaam.org or via phone at: 708-572-8006.
We look forward to your participation.
Sincerely,
Lara Renucci
AOAAM PCSS-MAT Data Manager
Funding for this initiative was made possible (in part) by Physicians' Clinical Support System for Medication Assisted Treatment (1U79TI024697) from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Printer-Friendly Version
Add to Calendar
aCLuDhaqizCaPxAftmqF167204
10/30/2013
10/30/2013
true
Office-Based Treatment For Opioid Use Disorders Webinar
The American Osteopathic Academy of Addiction Medicine (AOAAM) invites you to join us for a live webcast training on the Office-Based Treatment of Opioid Dependence utilizing Buprenorphine, with an additional focus on Methadone and Naltrexone. The program will provide up-to-date and evidence-based information to support training of health professionals and to address complex issues of addiction.
Saturday Presenter:Stephen A. Wyatt, DOAddiction Psychiatrist, Co-Chair SAMHSA Buprenorphine Expert Panel,Middlesex Hospital, Middletown, CT
Wednesday Presenter:William R. Morrone, DO, MS, ACOFP, ASAM, DAAPM, FACFEIAssistant Program Director - Family MedicineConsultant to Department of PsychiatryConsultant to Department of PediatricsSynergy Medical Education AllianceMichigan State UniversityCentral Michigan University - School of MedicineOffice of the Medical Examiner
Other Presenters:Anthony Dekker, DO, FACOFP, FAOAAM Director of Addiction MedicineDirectorate of Behavioral HealthFt. Belvoir Community HospitalFt. Belvoir, VA 22060
Click here to register for the Oct 12th webinar! Click here to register for the Oct 30th webinar! Click here to register for the Nov 9th webinar! Click here to register for the Nov 20th webinar!
Register ASAP as space is limited. This live webcast, in conjunction with a 3.75 hour online self-study and exam, will provide the required 8 hours needed to obtain the waiver to prescribe buprenorphine in the office based setting.
For questions, please contact Lara Renucci at pcssmat@aoaam.org or via phone at: 708-572-8006.
We look forward to your participation.
Sincerely,Lara RenucciAOAAM PCSS-MAT Data Manager
Funding for this initiative was made possible (in part) by Physicians' Clinical Support System for Medication Assisted Treatment (1U79TI024697) from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
----
